What Is SS-31 Studied For? Research Areas, Per the Literature

SS-31 is not approved by the FDA as a medicine for any condition. This page is not guidance. The sections below describe what published studies have examined, the type of study involved, and the model or population used. Nothing here is a recommendation, and no part of this page describes how a compound would be administered.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, symptom or treatment decision. For background on the molecule itself, see the overview hub at /learn/ss-31/.

What SS-31 Is, in the Literature

SS-31 is the research designation for a short synthetic peptide also referred to as elamipretide. A 2025 narrative review of its structure and mechanism described elamipretide as a mitochondria targeted tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane and has been investigated across a range of conditions linked to mitochondrial dysfunction (PMID 39940712). That same review framed the compound's therapeutic potential as an area of continuing investigation rather than settled clinical practice (PMID 39940712).

The broader rationale for studying any mitochondria directed agent was set out in a 2014 review of mitochondrial oxidative stress in aging and healthspan, which examined the proposition that mitochondrial reactive oxygen species contribute to age related functional decline (PMID 24860647). That review was mechanistic and conceptual, not a trial of any specific compound (PMID 24860647).

Research Areas at a Glance

Cardiac Aging and Heart Protein Chemistry

One of the clearer preclinical lines concerns the aging heart. A 2021 animal study in GeroScience reported that elamipretide treatment attenuated age associated post translational modifications of heart proteins in mice (PMID 34480713). The study was conducted in aged mice and examined protein level changes in cardiac tissue rather than clinical endpoints such as survival or symptom scores (PMID 34480713).

Findings of that kind are hypothesis generating. Researchers used them to argue that cardiolipin directed peptides deserve further testing, and the 2025 mechanism review placed cardiac applications among the most studied directions for elamipretide (PMID 39940712). Mouse heart biochemistry does not establish an effect in people.

Neuroinflammation, Synaptic Function and Memory

A 2019 animal study published in the Journal of Neuroinflammation reported that elamipretide improved mitochondrial dysfunction and reduced synaptic and memory impairment induced by lipopolysaccharide in mice (PMID 31747905). The model used bacterial lipopolysaccharide to provoke an inflammatory response in the brain, which is a standard laboratory challenge rather than a model of any specific human diagnosis (PMID 31747905).

Searches that pair SS-31 with cognition or neurodegeneration land on this kind of rodent work. The mechanistic review described neurological indications as an area of interest for mitochondria targeted peptides, again without presenting them as established therapy (PMID 39940712).

Skeletal and Respiratory Muscle

Muscle biology is another recurring theme. A 2018 study in Free Radical Biology and Medicine examined crosstalk between autophagy and oxidative stress in the regulation of diaphragm proteolysis during mechanical ventilation, using an animal model of prolonged ventilation (PMID 29197632). That work addressed ventilator associated diaphragm weakness, a hospital setting problem, and focused on signalling pathways linking redox state to protein breakdown (PMID 29197632).

Athletic Performance and Injury Recovery

A 2026 review in Sports Medicine evaluated the safety and efficacy of approved and unapproved peptide therapies marketed in connection with musculoskeletal injuries and athletic performance, and it characterised the supporting evidence for many such peptides as limited and largely preclinical (PMID 41966639). That review is the most directly relevant citation for anyone asking whether peptide compounds have demonstrated performance or recovery benefits in athletes, and it did not describe such benefits as established (PMID 41966639).

Eye Research: Age Related Macular Degeneration

A 2021 review in Cells surveyed potential therapeutic candidates for age related macular degeneration and included mitochondria directed approaches among the strategies under evaluation for retinal pigment epithelium dysfunction (PMID 34572131). Because the article was a review of candidates, it summarised rationale and early data rather than reporting a new controlled trial (PMID 34572131).

Metabolic and Liver Research

A 2023 review in Life Sciences examined the emerging significance of mitochondrial targeted strategies in the treatment of non alcoholic fatty liver disease, discussing why hepatic mitochondrial dysfunction has attracted interest as a target (PMID 37454757). The review was narrative in form and described a field in development rather than an approved treatment pathway (PMID 37454757).

Adjacent Bioengineering Literature

Several recent papers sit alongside the SS-31 literature because they concern mitochondria directed or antioxidant peptide chemistry rather than SS-31 itself. A 2024 review in the Journal of Biotechnology covered nanozymes designed to target mitochondrial repair in disease treatment, describing a materials science approach to the same biological problem (PMID 39159753). A 2025 laboratory study in ACS Applied Materials and Interfaces reported a coacervate built from polyphosphate and an antioxidant peptide that delivered microRNA in vitro (PMID 40478241). A 2025 study in Trends in Biotechnology reported that reprogrammed regulatory T cell derived small extracellular vesicles prevented intestinal inflammation from PANoptosis by blocking mitochondrial oxidative stress in a preclinical model (PMID 39689981). These papers illustrate how mitochondrial oxidative stress is being targeted by different tools; they are not evidence of clinical effects for SS-31 in people.

Safety Observations: What Studies Report

Safety information in the verified literature summarised here is general rather than granular. The 2025 structure and mechanism review discussed elamipretide's development and therapeutic potential and did not present it as an approved therapy with an established consumer safety profile (PMID 39940712). The 2026 Sports Medicine review addressed safety and efficacy of approved and unapproved peptide therapies together and emphasised that unapproved peptides lack the regulatory review that would characterise their risks (PMID 41966639).

The animal studies cited on this page reported biological outcomes in rodents, including cardiac protein modifications in aged mice (PMID 34480713) and memory and synaptic measures after an inflammatory challenge in mice (PMID 31747905). Animal safety signals do not transfer directly to humans, and no dosing information appears on this page because the verified citation set does not support any.

Where the Evidence Is Weak or Absent

• Athletic performance and recovery: a 2026 review characterised evidence for peptides promoted for musculoskeletal injury and performance as limited (PMID 41966639).
• Anti aging claims: the 2014 review discussed mitochondrial oxidative stress as a hypothesis about aging biology, not as a validated intervention target (PMID 24860647), while the heart protein data came from mice (PMID 34480713).
• Cognition: the supporting work is a mouse inflammation model, not a human trial (PMID 31747905).
• Eye and liver disease: the available citations are reviews of candidate strategies rather than outcome trials (PMID 34572131, PMID 37454757).

How to Read Claims About SS-31

1. Check whether the source was in vitro, animal or human. Most SS-31 findings cited here were animal or review level (PMID 31747905).
2. Check whether the paper measured a biomarker or a clinical outcome; the aged mouse cardiac study measured protein modifications (PMID 34480713).
3. Check whether a review is summarising rationale or reporting new data, as with the mitochondrial strategies review in fatty liver disease (PMID 37454757).
4. Check regulatory status separately from scientific interest, a distinction the peptide therapies review stressed (PMID 41966639).

Summary

Across the verified literature, SS-31 has been studied mainly in the context of mitochondrial dysfunction: cardiac aging biology in mice (PMID 34480713), neuroinflammation and memory in mice (PMID 31747905), muscle proteolysis during mechanical ventilation in an animal model (PMID 29197632), and review level discussion of retinal, hepatic and mechanistic questions (PMID 34572131, PMID 37454757, PMID 39940712). SS-31 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on anything read here.

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice (Journal of Neuroinflammation, 2019)
• Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins (GeroScience, 2021)
• Crosstalk between autophagy and oxidative stress regulates proteolysis in the diaphragm during mechanical ventilation (Free Radical Biology & Medicine, 2018)
• Mitochondrial oxidative stress in aging and healthspan (Longevity & Healthspan, 2014)
• Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD) (Cells, 2021)
• The emerging significance of mitochondrial targeted strategies in NAFLD treatment (Life Sciences, 2023)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Nanozymes targeting mitochondrial repair in disease treatment (Journal of Biotechnology, 2024)
• Polyphosphate- and Antioxidant Peptide-Based Coacervate Delivers miRNA (ACS Applied Materials & Interfaces, 2025)
• Reprogramming of Treg cell-derived small extracellular vesicles effectively prevents intestinal inflammation from PANoptosis by blocking mitochondrial oxidative stress (Trends in Biotechnology, 2025)